Ourania Tatsis Vertex Pharmaceuticals Inc (VRTX) insider trading activity

Ourania Tatsis is EVP, Chief Reg. & Quality Off. of VERTEX PHARMACEUTICALS INC . Currently has a direct ownership of 51,239 shares of VRTX, which is worth approximately $22.7 Million. The most recent transaction as insider was on Aug 23, 2023, when has been sold 2,500 shares (Common Stock) at a price of $355.0 per share, resulting in proceeds of $887,500. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 51.2K

0% 3M change

4.36% 12M change

Total Value Held $22.7 Million

Ourania Tatsis Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 23 2023	SELL Open market or private sale	$887,500 $355.0 p/Share	2,500 Reduced 4.89%	48,637 Common Stock
Aug 10 2023	SELL Open market or private sale	$1,988,292 $345.79 p/Share	5,750 Reduced 10.11%	51,137 Common Stock
Feb 27 2023	SELL Open market or private sale	$102,047 $288.27 p/Share	354 Reduced 0.62%	56,805 Common Stock
Feb 24 2023	SELL Payment of exercise price or tax liability	$956,408 $289.12 p/Share	3,308 Reduced 5.47%	57,159 Common Stock
Feb 21 2023	SELL Open market or private sale	$140,692 $293.11 p/Share	480 Reduced 0.79%	60,467 Common Stock
Feb 17 2023	SELL Payment of exercise price or tax liability	$1,317,239 $292.85 p/Share	4,498 Reduced 6.87%	60,947 Common Stock
Feb 14 2023	SELL Open market or private sale	$95,395 $298.11 p/Share	320 Reduced 0.49%	65,445 Common Stock
Feb 13 2023	SELL Open market or private sale	$82,148 $298.72 p/Share	275 Reduced 0.42%	65,765 Common Stock
Feb 13 2023	SELL Payment of exercise price or tax liability	$893,288 $298.26 p/Share	2,995 Reduced 4.34%	66,040 Common Stock
Feb 10 2023	SELL Payment of exercise price or tax liability	$405,292 $294.33 p/Share	1,377 Reduced 1.96%	69,035 Common Stock
Feb 01 2023	BUY Grant, award, or other acquisition	-	24,322 Added 25.67%	70,412 Common Stock
Aug 09 2022	SELL Open market or private sale	$419,552 $299.68 p/Share	1,400 Reduced 2.95%	46,090 Common Stock
Mar 17 2022	SELL Open market or private sale	$710,148 $250.67 p/Share	2,833 Reduced 5.64%	47,356 Common Stock
Feb 25 2022	SELL Open market or private sale	$75,056 $230.94 p/Share	325 Reduced 0.64%	50,189 Common Stock
Feb 24 2022	SELL Payment of exercise price or tax liability	$590,157 $227.86 p/Share	2,590 Reduced 4.88%	50,514 Common Stock
Feb 18 2022	SELL Open market or private sale	$120,076 $231.36 p/Share	519 Reduced 0.97%	53,104 Common Stock
Feb 17 2022	SELL Payment of exercise price or tax liability	$956,546 $232.51 p/Share	4,114 Reduced 7.13%	53,623 Common Stock
Feb 11 2022	SELL Open market or private sale	$68,263 $235.39 p/Share	290 Reduced 0.5%	57,737 Common Stock
Feb 10 2022	SELL Payment of exercise price or tax liability	$292,420 $237.74 p/Share	1,230 Reduced 2.08%	58,027 Common Stock
Feb 01 2022	BUY Grant, award, or other acquisition	-	27,714 Added 31.87%	59,257 Common Stock
Feb 24 2021	SELL Payment of exercise price or tax liability	$225,403 $217.57 p/Share	1,036 Reduced 3.19%	31,432 Common Stock
Feb 17 2021	SELL Payment of exercise price or tax liability	$423,500 $211.75 p/Share	2,000 Reduced 5.8%	32,468 Common Stock
Feb 10 2021	SELL Payment of exercise price or tax liability	$263,417 $214.16 p/Share	1,230 Reduced 3.45%	34,468 Common Stock
Feb 03 2021	BUY Grant, award, or other acquisition	-	22,960 Added 39.14%	35,698 Common Stock

Also insider at

VERV

Verve Therapeutics, Inc. Healthcare

Ourania Tatsis

EVP, Chief Reg. & Quality Off.

Boston, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells VRTX shares.

Notify only if

Value

Insider Trading

Get notified when an Vertex Pharmaceuticals Inc insider buys or sells VRTX shares.

Notify only if

Operation

Value

Type

News

Receive news related to VERTEX PHARMACEUTICALS INC

Track Activities on VRTX

Account